Infinimmune Enters Collaboration with Merck to Discover Novel Human Antibody Therapeutics

Infinimmune, a biotechnology company pioneering antibody discovery, is collaborating with Merck, known as MSD outside of the United States and Canada, to apply Infinimmune’s human-first antibody discovery platform to identify and develop antibody candidates against multiple undisclosed targets designated by Merck. 

It enables the screening of millions of single memory B cells across hundreds of potential targets, identifying natively paired antibody candidates and enabling the rapid identification of candidates with strong affinity, specificity, and favourable drug-like properties. 

According to Towards Healthcare, the stem cell research antibodies market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 2.03 billion in 2026 to approximately USD 4.71 billion by 2035, representing a compound annual growth rate (CAGR) of 9.8% from 2026 to 2035. Growth is driven by the increasing prevalence of chronic diseases and the rising demand for targeted regenerative therapies, and the need for high-quality antibodies essential for cell identification, sorting, and functional analysis. 

About Infinimmune 

Infinimmune is a biotechnology company developing next-generation antibody therapeutics by discovering antibodies directly from the human immune system. This platform enables the screening of millions of single memory B cells to identify fully human antibodies across hundreds of targets.  

Combined with the company’s GLIMPSE antibody language model, this approach enables the rapid discovery and optimisation of antibodies with strong affinity, specificity, and favourable developability characteristics. 

Its main mission is to revolutionise antibody drug discovery by utilising the vast diversity of human antibodies. The company believes that the human body is the most advanced laboratory for antibody development, generating approximately 100 billion antibodies daily. 

CEO and co-founder, Infinimmune, Ph.D. Wyatt McDonnell said we are excited to work with Merck to apply our platform to the discovery of novel antibody therapeutics. 

A recent report by Towards Healthcare highlights that the stem cell research antibodies market is witnessing growth due to growing understanding of stem cell applications in regenerative medicine, leading to a higher demand for antibodies that facilitate the identification and characterization of stem cell markers.  

North America dominated the stem cell research antibodies market, with Asia-Pacific being the fastest-growing region. The growth in these regions is driven by the increasing demand for targeted regenerative therapies and advancements in stem cell-based therapies. The rising prevalence of chronic diseases is also fueling the growth of the market.